|
WO1997030035A1
(en)
|
1996-02-13 |
1997-08-21 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
|
ES2169355T3
(es)
|
1996-03-05 |
2002-07-01 |
Astrazeneca Ab |
Derivados de 4-anilinoquinazolina.
|
|
HRP970371A2
(en)
*
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
WO1999024440A1
(en)
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
WO1999038845A1
(en)
|
1998-01-29 |
1999-08-05 |
Tularik Inc. |
Ppar-gamma modulators
|
|
SE514237C2
(sv)
|
1998-02-26 |
2001-01-29 |
Ericsson Telefon Ab L M |
Utbytbart kontaktdon för inbördes roterande enheter och en bärbar anordning försedd med sådant kontaktdon
|
|
PL198640B1
(pl)
|
1998-06-19 |
2008-07-31 |
Pfizer Prod Inc |
Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
AU2012209038B2
(en)
*
|
1998-09-29 |
2013-09-26 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
AU6159499A
(en)
*
|
1998-09-29 |
2000-04-17 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
EP1192151B1
(en)
*
|
1999-07-09 |
2007-11-07 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
CN100376567C
(zh)
|
1999-11-05 |
2008-03-26 |
阿斯特拉曾尼卡有限公司 |
作为vegf抑制剂的喹唑啉衍生物
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
|
EA006227B1
(ru)
|
1999-12-10 |
2005-10-27 |
Пфайзер Продактс Инк. |
СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
|
|
CA2395520A1
(en)
|
1999-12-21 |
2001-06-28 |
Sugen, Inc. |
4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
|
|
EP1990343B1
(en)
|
1999-12-24 |
2012-04-04 |
Aventis Pharma Limited |
Azaindoles
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
EA006153B1
(ru)
|
2000-06-26 |
2005-10-27 |
Пфайзер Продактс Инк. |
СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
|
|
US20030171399A1
(en)
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
BR0111947A
(pt)
*
|
2000-06-30 |
2003-05-06 |
Glaxo Group Ltd |
Composto, composição farmacêutica, método para o tratamento de um distúrbio em um mamìfero, uso de um composto e processo para preparar, um composto
|
|
EP1415987B1
(en)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Nitrogenous aromatic ring compounds as anti cancer agents
|
|
KR20020051675A
(ko)
*
|
2000-12-23 |
2002-06-29 |
이상남 |
4-페닐아미노티에노 [3,2-디] 피리미딘 유도체 및 이의제조방법
|
|
PA8535501A1
(es)
|
2001-01-05 |
2003-07-28 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
|
EP1353693B1
(en)
|
2001-01-16 |
2005-03-16 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
|
|
EP1249451B1
(en)
|
2001-04-13 |
2006-06-21 |
Pfizer Products Inc. |
Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115109D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
CN1627944A
(zh)
*
|
2002-01-17 |
2005-06-15 |
神经能质公司 |
取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
|
|
JP2005527511A
(ja)
|
2002-03-01 |
2005-09-15 |
ファイザー インコーポレイテッド |
抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
|
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
|
WO2003086467A1
(en)
*
|
2002-04-08 |
2003-10-23 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
ATE360015T1
(de)
*
|
2002-07-31 |
2007-05-15 |
Critical Outcome Technologies |
Protein tyrosin kinase inhibitoren
|
|
ATE380810T1
(de)
*
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
|
AU2003276591A1
(en)
|
2002-11-26 |
2004-06-18 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
WO2004055003A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
JP3814285B2
(ja)
|
2002-12-19 |
2006-08-23 |
ファイザー・インク |
眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
|
|
EA013248B1
(ru)
|
2002-12-20 |
2010-04-30 |
Пфайзер Продактс Инк. |
Производные пиримидина для лечения патологического роста клеток
|
|
RS53118B
(sr)
|
2003-02-26 |
2014-06-30 |
Sugen Inc. |
Aminoheteroaril jedinjenja kao inhibitori protein kinaze
|
|
MXPA05012839A
(es)
*
|
2003-05-27 |
2006-05-17 |
Pfizer Prod Inc |
Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
|
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
EP1653986A4
(en)
*
|
2003-08-01 |
2007-03-14 |
Smithkline Beecham Corp |
TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2536321A1
(en)
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
|
JP4503022B2
(ja)
|
2003-12-23 |
2010-07-14 |
ファイザー・インク |
新規キノリン誘導体
|
|
US20050187389A1
(en)
*
|
2004-01-13 |
2005-08-25 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
|
US20080269238A1
(en)
*
|
2004-04-01 |
2008-10-30 |
Takeda Pharmaceutical Company Limited |
Thiazolopyrimidine Derivative
|
|
WO2005118588A1
(ja)
*
|
2004-06-02 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
縮合複素環化合物
|
|
CA2569404A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
|
RU2342159C2
(ru)
|
2004-07-16 |
2008-12-27 |
Пфайзер Продактс Инк. |
Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
|
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
|
BRPI0609655A2
(pt)
|
2005-03-31 |
2010-03-16 |
Agensys Inc |
anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
|
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
|
TW200740820A
(en)
*
|
2005-07-05 |
2007-11-01 |
Takeda Pharmaceuticals Co |
Fused heterocyclic derivatives and use thereof
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
KR101536506B1
(ko)
|
2005-09-07 |
2015-07-14 |
암젠 프레몬트 인코포레이티드 |
액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CA2623125A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US7910595B2
(en)
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
|
CN102702194A
(zh)
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
|
BRPI0720169A2
(pt)
|
2006-12-12 |
2013-12-24 |
Takeda Pharmaceutical |
Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
|
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
CA2673683C
(en)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
MX2009010517A
(es)
|
2007-04-05 |
2009-10-19 |
Amgen Inc |
Moduladores de cinasa aurora y metodos de uso.
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
AP2009005010A0
(en)
|
2007-04-18 |
2009-10-31 |
Pfizer Prod Inc |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
|
PT2185574E
(pt)
|
2007-09-07 |
2013-08-26 |
Agensys Inc |
Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12
|
|
NZ585357A
(en)
|
2007-10-29 |
2012-02-24 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
|
JPWO2009113560A1
(ja)
|
2008-03-12 |
2011-07-21 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
JP2011515401A
(ja)
|
2008-03-20 |
2011-05-19 |
アムジエン・インコーポレーテツド |
オーロラキナーゼモジュレーターおよび使用方法
|
|
US8252805B2
(en)
|
2008-05-07 |
2012-08-28 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib ditosylate and processes for preparation thereof
|
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
US9126935B2
(en)
|
2008-08-14 |
2015-09-08 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
|
HRP20140395T1
(hr)
|
2008-08-20 |
2014-06-06 |
Zoetis Llc |
SPOJEVI PIROLO[2,3-d]PIRIMIDINA
|
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
|
WO2010045495A2
(en)
|
2008-10-16 |
2010-04-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
|
WO2010054264A1
(en)
|
2008-11-07 |
2010-05-14 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
JP5781934B2
(ja)
|
2008-11-10 |
2015-09-24 |
ナショナル ヘルス リサーチ インスティテューツ |
チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
|
|
CN101735200B
(zh)
*
|
2008-11-17 |
2013-01-02 |
岑均达 |
喹唑啉类化合物
|
|
JP2012517426A
(ja)
|
2009-02-09 |
2012-08-02 |
アステックス ファーマシューティカルズ インコーポレイテッド |
ピロロピリミジニルａｘｌキナーゼ阻害剤
|
|
US8569316B2
(en)
|
2009-02-17 |
2013-10-29 |
Boehringer Ingelheim International Gmbh |
Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
|
SG10201510152RA
(en)
|
2009-07-13 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
|
BR112012003592B8
(pt)
|
2009-08-19 |
2021-05-25 |
Eisai R&D Man Co Ltd |
composição farmacêutica contendo derivado de quinolina
|
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
|
SG179070A1
(en)
|
2009-09-11 |
2012-04-27 |
Genentech Inc |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
|
MX2012002909A
(es)
|
2009-09-17 |
2012-04-19 |
Hoffmann La Roche |
Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
|
|
EP2510110A1
(en)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
|
DK3150610T3
(da)
|
2010-02-12 |
2019-11-04 |
Pfizer |
Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
|
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
US8993634B2
(en)
|
2010-06-02 |
2015-03-31 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to Her2/neu receptor complex
|
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
|
WO2011153050A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
|
ES2611479T3
(es)
|
2010-06-16 |
2017-05-09 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Anticuerpos contra endoplasmina y su uso
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
CN103109189A
(zh)
|
2010-07-19 |
2013-05-15 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
EP2596359A1
(en)
|
2010-07-19 |
2013-05-29 |
F.Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
SG187592A1
(en)
|
2010-07-23 |
2013-03-28 |
Univ Boston |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
CA2813162C
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2- derivatives as smoothened receptor modulators
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
AU2012225232B2
(en)
|
2011-03-09 |
2016-05-12 |
Richard G. Pestell |
Prostate cancer cell lines, gene signatures and uses thereof
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
EP2700403B1
(en)
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
|
ES2575710T3
(es)
|
2011-09-22 |
2016-06-30 |
Pfizer Inc |
Derivados de pirrolopirimidina y purina
|
|
WO2013055530A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
|
HK1205522A1
(en)
|
2011-11-08 |
2015-12-18 |
辉瑞公司 |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
EP2861302A4
(en)
|
2012-05-14 |
2016-08-24 |
Prostagene Llc |
USE OF CCR5 MODULATORS FOR THE TREATMENT OF CANCER
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
|
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
CN105764511B
(zh)
|
2013-10-04 |
2019-01-11 |
艾普托斯生物科学公司 |
用于治疗癌症的组合物和方法
|
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
CN106536753B
(zh)
|
2014-04-04 |
2020-07-21 |
中美冠科生物技术（太仓）有限公司 |
用于确定对mek/erk抑制剂的应答性的方法
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
DK3137460T3
(da)
|
2014-04-30 |
2019-12-16 |
Pfizer |
Cycloalkyl-bundne diheterocyklusderivater
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
WO2016019280A1
(en)
|
2014-07-31 |
2016-02-04 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human monoclonal antibodies against epha4 and their use
|
|
CA2957005C
(en)
|
2014-08-28 |
2021-10-12 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
|
EP3237638B1
(en)
|
2014-12-24 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
EP3611506B1
(en)
|
2015-04-20 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
US10011629B2
(en)
|
2015-05-01 |
2018-07-03 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
|
PL3298021T3
(pl)
|
2015-05-18 |
2019-11-29 |
Tolero Pharmaceuticals Inc |
Proleki alvocidibu o zwiększonej biodostępności
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
CN111643479B
(zh)
|
2015-07-01 |
2023-10-27 |
加州理工学院 |
基于阳离子粘酸聚合物的递送系统
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
MX2018006781A
(es)
|
2015-12-03 |
2018-11-09 |
Agios Pharmaceuticals Inc |
Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
|
CA3048217A1
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
ES2905676T3
(es)
|
2017-05-22 |
2022-04-11 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos para su uso
|
|
CN111051306B
(zh)
|
2017-09-08 |
2023-01-03 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
|
WO2019241327A1
(en)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
|
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
CA3115038A1
(en)
|
2018-10-04 |
2020-04-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Egfr inhibitors for treating keratodermas
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP2022511029A
(ja)
|
2018-12-04 |
2022-01-28 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
|
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
MX2021007157A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
AU2020221247B2
(en)
|
2019-02-12 |
2024-12-12 |
Sumitomo Pharma America, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
|
EP3930845A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CN114144414B
(zh)
|
2019-05-21 |
2025-11-07 |
美国安进公司 |
固态形式
|
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CN114302880B
(zh)
|
2019-08-02 |
2025-07-15 |
美国安进公司 |
Kif18a抑制剂
|
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
US12540129B2
(en)
|
2019-08-02 |
2026-02-03 |
Amgen Inc. |
KIF18A inhibitors
|
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
|
PE20221277A1
(es)
|
2019-11-04 |
2022-09-05 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN114786777A
(zh)
|
2019-11-04 |
2022-07-22 |
锐新医药公司 |
Ras抑制剂
|
|
PE20230249A1
(es)
|
2019-11-08 |
2023-02-07 |
Revolution Medicines Inc |
Compuestos de heteroarilo biciclicos y usos de estos
|
|
CA3158188A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CA3163703A1
(en)
|
2020-01-07 |
2021-07-15 |
Steve Kelsey |
Shp2 inhibitor dosing and methods of treating cancer
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
AU2021345111B2
(en)
|
2020-09-15 |
2025-11-27 |
Revolution Medicines, Inc. |
Indole derivatives as Ras inhibitors in the treatment of cancer
|
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
IL314883A
(en)
|
2022-03-07 |
2024-10-01 |
Amgen Inc |
Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4601644A1
(en)
|
2022-10-14 |
2025-08-20 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
EP4688790A1
(en)
|
2023-04-07 |
2026-02-11 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
CN121712509A
(zh)
|
2023-05-04 |
2026-03-20 |
锐新医药公司 |
用于ras相关疾病或病症的组合疗法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
IL327306A
(en)
|
2023-10-12 |
2026-05-01 |
Revolution Medicines Inc |
Macrocyclic RAS inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|